Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.

Clinical pharmacology and therapeutics - 1 Nov 2004

Schalekamp Tom, Oosterhof Mirjam, van Meegen Erik, van Der Meer Felix J M, Conemans Jean, Hermans Mirjam, Meijerman Irma, de Boer Anthonius

Abstract excerpt

OBJECTIVE: Our objective was to assess whether there is an association between the presence of allelic variants of the gene for cytochrome P450 (CYP) 2C9 and anticoagulation problems during the initial phase of phenprocoumon treatment. METHODS: A prospective follow-up study was performed at 2 anticoagulation clinics in The Netherlands. Included subjects started phenprocoumon during the study period, had their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Endpoint Determination

Share to Netherlands

Share to Proportional Hazards Models

Source

Identifiers

PMID: 15536456
DOI: 10.1016/j.clpt.2004.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.PMID 15536456Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.Semantic proximity Read ↗

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.Semantic proximity Read ↗

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.Semantic proximity Read ↗

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.Semantic proximity Read ↗

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.